AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3885180 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP (Diphtheria-tetanus toxoids at 4 months, DTP at 6 months)
Number of subjects: 0
Study 3885180 — intervention group
Group type: COMPARATOR
Intervention: DTP-DTP-DT (DTP at 4 months, Diphtheria-tetanus toxoids at 6 months)
Number of subjects: 0
Study 3885180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DTP-DT-DTP and DTP-DTP-DT)
Number of subjects: 0
Study 3885180 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP
Number of subjects: 0
Study 3885180 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-DT-DTP and DTP-DTP-DT
Number of subjects: 0
Study 3370920 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 breathing
Number of subjects: 11
Study 3370920 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% O2 breathing
Number of subjects: 11
Study 3370920 — intervention group
Group type: COMPARATOR
Intervention: Air breathing
Number of subjects: 11
Study 29431852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 146
Study 29431852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 25815324 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein daily
Number of subjects: 112
Study 25815324 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lutein daily
Number of subjects: 112
Study 25815324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 mg lutein and 10 mg zeaxanthin daily
Number of subjects: 112
Study 25815324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 23918531 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy with pillar suturing
Number of subjects: 24
Study 23918531 — intervention group
Group type: COMPARATOR
Intervention: Adenotonsillectomy alone
Number of subjects: 24
Study 21925062 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD™), 4 capsules, 3 times a day for 3 months
Number of subjects: 80
Study 21925062 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 4 capsules, 3 times a day for 3 months
Number of subjects: 80
Study 21925062 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601 (NeuroAiD™)
Number of subjects: 80
Study 21925062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18283598 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel administered alone
Number of subjects: 0
Study 18283598 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 0
Study 18283598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD) with more than 300 mm2 of copper
Number of subjects: 0
Study 18283598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (selective progesterone receptor modulator)
Number of subjects: 0
Study 16457912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline 1:200,000
Number of subjects: 45
Study 16457912 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 45
Study 12692872 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachinaze (active device)
Number of subjects: 50
Study 12692872 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (control)
Number of subjects: 50
Study 10784334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercondylar width (ICW) measurements
Number of subjects: 27
Study 10784334 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices developed from ICW measurements
Number of subjects: 27
Study 8794800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone, 2.5 g
Number of subjects: 36
Study 8794800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 1 mg
Number of subjects: 36
Study 8794800 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐butylscopolamine, 20 mg
Number of subjects: 36
Study 8794800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol, 50 mg
Number of subjects: 36
Study 8794800 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 75 mg
Number of subjects: 36
Study 8794800 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 36
Study 1616158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (n = 20)
Number of subjects: 30
Study 1616158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg succinylcholine (n = 10)
Number of subjects: 30
Study 6379679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (400 mg/day)
Number of subjects: 95
Study 6379679 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg/day)
Number of subjects: 95
Study 31069787 — intervention group
Group type: EXPERIMENTAL
Intervention: High UVA-protection factor sunscreen (SPF 15)
Number of subjects: 20
Study 31069787 — intervention group
Group type: EXPERIMENTAL
Intervention: Low UVA-protection factor sunscreen (SPF 15)
Number of subjects: 20
Study 31069787 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary sunscreen use
Number of subjects: 20
Study 31069787 — intervention group
Group type: COMPARATOR
Intervention: Nonholiday group
Number of subjects: 20
Study 30280641 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide
Number of subjects: 403
Study 30280641 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide
Number of subjects: 403
Study 26120052 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (intramuscular testosterone undecanoate for 40 weeks)
Number of subjects: 88
Study 26120052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 40 weeks)
Number of subjects: 88
Study 25070809 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 100 mg/d
Number of subjects: 112
Study 25070809 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Therapy (MBSCT)
Number of subjects: 112
Study 25070809 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 112
Study 25070809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 112
Study 25070809 — intervention group
Group type: COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Treatment (BBCET)
Number of subjects: 112
Study 22585094 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week group treatment in addition to treatment as usual
Number of subjects: 71
Study 22585094 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 71
Study 20167847 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 vaccine
Number of subjects: 0
Study 18499959 — intervention group
Group type: COMPARATOR
Intervention: SHBG levels in hirsute girls (FG > 4)
Number of subjects: 252
Study 18499959 — intervention group
Group type: COMPARATOR
Intervention: FT levels in hirsute girls (FG > 4)
Number of subjects: 252
Study 18499959 — intervention group
Group type: COMPARATOR
Intervention: FT levels in hirsute subjects (FG > 4)
Number of subjects: 252
Study 18499959 — intervention group
Group type: COMPARATOR
Intervention: Correlation of FG with SHBG
Number of subjects: 252
Study 18499959 — intervention group
Group type: COMPARATOR
Intervention: Correlation of FG with FT
Number of subjects: 252
Study 18499959 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG values
Number of subjects: 252
Study 18499959 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope of SHBG decrease
Number of subjects: 252
Study 18499959 — intervention group
Group type: EXPERIMENTAL
Intervention: FT values
Number of subjects: 252
Study 15827938 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep heating (SWD)
Number of subjects: 24
Study 15827938 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heating (hot packs)
Number of subjects: 24
Study 15827938 — intervention group
Group type: COMPARATOR
Intervention: No heating
Number of subjects: 24
Study 11216733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 50
Study 11216733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 50
Study 11216733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50
Study 11216733 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 50
Study 11216733 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 9462588 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (APAs)
Number of subjects: 6797
Study 9462588 — intervention group
Group type: COMPARATOR
Intervention: Enalapril therapy
Number of subjects: 6797
Study 8046423 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent vaccine (1 x 10(4) PFU each of D x RRV and RRV, followed 4 weeks later by 1 x 10(4) PFU each of DS1 x RRV and ST3 x RRV)
Number of subjects: 100
Study 8046423 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent vaccine (10(4) PFU of each component)
Number of subjects: 100
Study 8046423 — intervention group
Group type: COMPARATOR
Intervention: M37 vaccine (10(4) PFU)
Number of subjects: 100
Study 8046423 — intervention group
Group type: COMPARATOR
Intervention: Higher-titered quadrivalent vaccine (10(5) PFU of each component)
Number of subjects: 100
Study 8046423 — intervention group
Group type: COMPARATOR
Intervention: Higher-titered M37 vaccine (10(5) PFU)
Number of subjects: 100
Study 2902873 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 9
Study 2902873 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol
Number of subjects: 9
Study 31868889 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy A - Bolus water drinking + physical counter‐manoeuvres (PCM)
Number of subjects: 37
Study 31868889 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy B - Bolus water drinking + PCM + abdominal compression
Number of subjects: 37
Study 31868889 — intervention group
Group type: COMPARATOR
Intervention: Single therapy (bolus water drinking)
Number of subjects: 37
Study 31017476 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33 °C
Number of subjects: 171
Study 31017476 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36 °C
Number of subjects: 171
Study 28387855 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 94
Study 28387855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 25840898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management program on home exercise training
Number of subjects: 113
Study 25840898 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 113
Study 23660397 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSO-524 (Lyprinol/Omega XL)
Number of subjects: 20
Study 21542001 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid (5 mg)
Number of subjects: 7736
Study 19486788 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of uninterrupted bed rest with music (soft and relaxing, new-age style, 50 to 60 dB, through a music pillow connected to an MP3 player)
Number of subjects: 58
Study 19486788 — intervention group
Group type: COMPARATOR
Intervention: 60 minutes of uninterrupted bed rest (control group)
Number of subjects: 58
Study 17596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal fetal surveillance in women with milder degrees of GDM
Number of subjects: 0
Study 17596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal timing and mode of delivery
Number of subjects: 0
Study 17596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal and pelvic imaging techniques
Number of subjects: 0
Study 14969566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 0
Study 14969566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11409665 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis educational program (OEP), 3-hour duration
Number of subjects: 100
Study 11409665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 9684701 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH) (6,160 IU +/- 1,350 IU)
Number of subjects: 11
Study 9684701 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) (15 anti-Xa U/kg + 5 anti-Xa U/kg/h)
Number of subjects: 11
Study 9684701 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH)
Number of subjects: 11
Study 9684701 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 11
Study 7849748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 24
Study 7849748 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace
Number of subjects: 24
Study 7849748 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 24
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (divided dose)
Number of subjects: 0
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (single dose)
Number of subjects: 0
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (divided dose)
Number of subjects: 0
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0
Study 2904367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1 (divided dose)
Number of subjects: 0
Study 29727011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation without neuromuscular blockade
Number of subjects: 248
Study 29727011 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation with neuromuscular blockade (rocuronium)
Number of subjects: 248
Study 28536701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-type respirator
Number of subjects: 24
Study 28536701 — intervention group
Group type: COMPARATOR
Intervention: Fold-type respirator without a valve
Number of subjects: 24
Study 28536701 — intervention group
Group type: COMPARATOR
Intervention: Fold-type respirator with a valve
Number of subjects: 24
Study 26460536 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic CBT (TD‐CBT)
Number of subjects: 338
Study 26460536 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-specific CBT (DS‐CBT)
Number of subjects: 338
Study 23880091 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra(®)
Number of subjects: 10
Study 23880091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellonex™
Number of subjects: 10
Study 23880091 — intervention group
Group type: EXPERIMENTAL
Intervention: Split thickness skin graft (STSG)
Number of subjects: 10
Study 23880091 — intervention group
Group type: COMPARATOR
Intervention: All materials
Number of subjects: 10
Study 23880091 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 10
Study 21270326 — intervention group
Group type: EXPERIMENTAL
Intervention: iv recombinant hCG (1, 10, 25, 100, and 250 μg)
Number of subjects: 21
Study 21270326 — intervention group
Group type: EXPERIMENTAL
Intervention: iv recombinant hCG (25 μg)
Number of subjects: 21
Study 21270326 — intervention group
Group type: COMPARATOR
Intervention: Normal women (control group)
Number of subjects: 21
Study 19481579 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Number of subjects: 252
Study 19481579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Number of subjects: 252
Study 19481579 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid and gluteal injections of paliperidone palmitate
Number of subjects: 252
Study 16923411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid multivitamin (5 mg folic acid, 50 mg vitamin B6, 1000 microg vitamin B12)
Number of subjects: 4000
Study 16923411 — intervention group
Group type: COMPARATOR
Intervention: Low-dose folic acid multivitamin (0 mg folic acid, 1.4 mg vitamin B6, 2 microg vitamin B12)
Number of subjects: 4000
Study 14970765 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment using pulsed electromagnetic fields
Number of subjects: 76
Study 14970765 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 76
Study 14970765 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for patients with anterior disk displacement without reduction
Number of subjects: 76
Study 14970765 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for patients with osteoarthritis
Number of subjects: 76
Study 14970765 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for patients with anterior disk displacement with reduction
Number of subjects: 76
Study 11296449 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD-CPR
Number of subjects: 64
Study 11296449 — intervention group
Group type: COMPARATOR
Intervention: STD-CPR
Number of subjects: 64
Study 11296449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ACD-CPR and STD-CPR)
Number of subjects: 64
Study 11296449 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ROSC cases
Number of subjects: 64
Study 9746450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0
Study 9746450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2330731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day treatment with sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21
Study 2330731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment with regular sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21
Study 2330731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day treatment with reduced sulfamerazine/trimethoprim (Berlocombin)
Number of subjects: 21
Study 449434 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized medical record summary system
Number of subjects: 479
Study 449434 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical record
Number of subjects: 479
Study 31012742 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Self‐Conscious Affect‐3 (TOSCA‐3)
Number of subjects: 138
Study 31012742 — intervention group
Group type: COMPARATOR
Intervention: Personal Feelings Questionnaire‐2 (PFQ‐2)
Number of subjects: 138
Study 31486729 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based ACP using the Serious Illness Care Program (SICP)
Number of subjects: 1260
Study 31486729 — intervention group
Group type: COMPARATOR
Intervention: Clinician-focused ACP using the Serious Illness Care Program (SICP)
Number of subjects: 1260
Study 28626257 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping exercises in the Hand Incubator device for 4 weeks
Number of subjects: 24
Study 28626257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 25776739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene (XLK)
Number of subjects: 0
Study 25776739 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene (GVF)
Number of subjects: 0
Study 24585363 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release including release of the rotator interval and anterior and inferior capsule (Group I, n = 37)
Number of subjects: 75
Study 24585363 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic capsular release extended to the posterior capsule (Group II, n = 38)
Number of subjects: 75
Study 22215856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 0
Study 22215856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 0
Study 22215856 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 20141630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy using liquid nitrogen for a maximum of 4 treatments (2-3 weeks apart)
Number of subjects: 266
Study 20141630 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid (50%) self-treatment for a maximum of 8 weeks
Number of subjects: 266
Study 18043528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for 12 weeks
Number of subjects: 31
Study 18043528 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 31
Study 16086929 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (hours per day)
Number of subjects: 874
Study 16086929 — intervention group
Group type: COMPARATOR
Intervention: Various treatment arms
Number of subjects: 874
Study 12171841 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC‐FP 500 microg/d
Number of subjects: 18
Study 12171841 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC‐FP 1000 microg/d
Number of subjects: 18
Study 12171841 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐FP 500 microg/d
Number of subjects: 18
Study 12171841 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA‐FP 1000 microg/d
Number of subjects: 18
Study 12171841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10354026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate on Sunday, Tuesday and Thursday (group A)
Number of subjects: 120
Study 10354026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate on Saturday and Sunday (group B)
Number of subjects: 120
Study 10354026 — intervention group
Group type: COMPARATOR
Intervention: No further corticosteroid treatment (group C)
Number of subjects: 120
Study 8965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness program
Number of subjects: 1147
Study 8965290 — intervention group
Group type: EXPERIMENTAL
Intervention: School and home nutrition
Number of subjects: 1147
Study 8965290 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nutrition
Number of subjects: 1147
Study 8965290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1147
Study 1354687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (dl-alpha-tocopherol nicotinate, 200 mg, tid)
Number of subjects: 15
Study 1354687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (200 mg, tid)
Number of subjects: 15
Study 1354687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (in vitro, 0.1 to 3.0 mM)
Number of subjects: 15